alpha-Melanocyte-stimulating hormone
| Names | |
|---|---|
| IUPAC name
N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-α-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valinamide | |
| Other names
alpha-MSH, α-melanocortin, α-melanotropin, α-intermedin; Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 | |
| Identifiers | |
581-05-5  | |
| ChEMBL | ChEMBL385886  |
| ChemSpider | 17289286 |
| PubChem | 16132636 |
| |
| Properties | |
| C77H109N21O19S | |
| Molar mass | 1664.884 g/mol |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| verify (what is ?) | |
| Infobox references | |
α-Melanocyte-stimulating hormone (α-MSH) is an endogenous peptide hormone and neuropeptide of the melanocortin family, with a tridecapeptide structure and the amino acid sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. It is the most important of the melanocyte-stimulating hormones (MSHs) (also known as melanotropins) in stimulating melanogenesis, a process that in mammals (including humans) is responsible for pigmentation primarily of the hair and skin. It also plays a role in feeding behavior, energy homeostasis, sexual activity, and protection against ischemia and reperfusion injury.[1]
α-MSH is a non-selective full agonist of the melanocortin receptors MC1 (Ki = 0.230 nM), MC3 (Ki = 31.5 nM), MC4 (Ki = 900 nM), and MC5 (Ki = 7160 nM), but not MC2 (which is exclusive for adrenocorticotropic hormone (ACTH)).[2] Activation of the MC1 receptor is responsible for its effect on pigmentation, whereas its regulation of appetite, metabolism, and sexual behavior is mediated through both the MC3 and MC4 receptors.
It is generated as a proteolyic cleavage product from ACTH (1-13), which is in turn a cleavage product of proopiomelanocortin (POMC).
A few synthetic analogues of α-MSH have been investigated as medicinal drugs due to their photoprotective effects against ultraviolet (UV) radiation from the sun. They include afamelanotide (melanotan) and melanotan II, the former of which being in phase-III clinical trials in the United States. Bremelanotide, another analogue of α-MSH, is currently under development not as a photoprotective agent, but instead for the treatment of sexual dysfunction. All of these drugs have significantly greater potencies than α-MSH, along with improved pharmacokinetics and distinctive selectivity profiles.
See also
References
- ↑ Varga, B.; Gesztelyi, R.; Bombicz, M.; Haines, D.; Szabo, A. M.; Kemeny-Beke, A.; Antal, M.; Vecsernyes, M.; Juhasz, B.; Tosaki, A. (July 2013). "Protective effect of alpha-melanocyte-stimulating hormone (α-MSH) on the recovery of ischemia/reperfusion (I/R)-induced retinal damage in a rat model". Journal of Molecular Neuroscience 50 (3): 558–70. doi:10.1007/s12031-013-9998-3. PMID 23504281.
- ↑ Schiöth, Helgi B; Mutulis, Felikss; Muceniece, Ruta; Prusis, Peteris; Wikberg, Jarl E S (1998). "Discovery of novel melanocortin4receptor selective MSH analogues". British Journal of Pharmacology 124 (1): 75–82. doi:10.1038/sj.bjp.0701804. ISSN 0007-1188.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Friday, October 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.